Journal of Addictive Diseases
2024
Alexandra Arenson, Cynthia I Campbell, Ilan Remler
8 citations
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...
December 26, 2023
Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al.
preprint
Background: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain...
The Oxford Handbook of Opioids and Opioid Use Disorder
December 18, 2023
Deborah C. Mash, Michael Karukin
Abstract Ibogaine is an indole alkaloid derived from the root bark of Tabernanthe iboga. The anti-addictive actions of ibogaine were first reported in the 1960s by persons using heroin. They offered personal testimonials that single oral doses of ibogaine abruptly blocked opioid withdrawal, and they remained drug-free after ibogaine exposure. Today, online forums describe ibogaine use for...
Brazilian Journal of Health Review
December 15, 2023
Fernanda Leticia Dos Santos Matta, Vivian Frigo Batista, Alexandre Dantas Gimenes et al.
A Ibogaína é um alcalóide indólico psicoativo com efeitos estimulantes e alucinógenos o qual é derivado da casca da raiz do arbusto da África Ocidental Tabernanthe iboga, mostra-se uma alternativa promissora no tratamento de dependentes de substâncias derivadas do ópio por demonstrar uma afinidade significativa por muitos sistemas neurotransmissores. Avaliar os efeitos do tratamento com...
Psychoactives
December 11, 2023
Juliana Mendes Rocha, José Augusto Silva Reis, Giordano Novak Rossi et al.
3 citations
As the research field with psychedelic substances grows, it is expected to encompass a more extensive cohort of individuals presenting a spectrum of medical conditions, comorbidities, and unique physiological traits, thereby increasing the likelihood of potential adverse events. Furthermore, it is worth noting that there is a scarcity of the specialized literature regarding procedures to ensure...
Journal of Psychopharmacology
December 1, 2023
Genís Ona, Ingrid Reverte, Giordano N. Rossi et al.
20 citations
There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism of...
The MIT Press eBooks
November 21, 2023
Julien Bonhomme
1 citation
International audience
Journal of the International Neuropsychological Society
November 1, 2023
Kirsten Cherian, Afik Faerman, Lauren Anker et al.
Objective: To determine the effects of the non-classic psychedelic, ibogaine, on cognitive functioning. Ibogaine is an indole alkaloid derived from the Tabernanthe Iboga plant family, indigenous to Africa, and traditionally used in spiritual and healing ceremonies. Ibogaine has primarily been studied with respect to its clinical efficacy in reducing substance addiction. There are, however,...
October 1, 2023
Sarah Falkenhaug
1 citation
Substance use disorders are a debilitating psychiatric condition which contribute to significant personal, legal and economic problems worldwide. Current treatment options, such as pharmaceutical interventions or behavioural therapy, are not always utilised or effective at reducing symptoms. Ibogaine, a psychedelic compound deriving from root bark of the Tabernanthe iboga plant, has shown...
European Archives of Psychiatry and Clinical Neuroscience
October 1, 2023
Juliana Mendes Rocha, José A S Reis, José Carlos Bouso et al.
21 citations
Ibogaine is a psychoactive alkaloid derived from the west-African shrub Tabernanthe iboga. Western cultures are increasing the interest for the substance due to its claimed anti addictive properties, although the evidence supporting this effect is still preliminary. The use of ibogaine often occurs with no medical supervision in uncontrolled settings, and its use has been associated with...